Professor Nigel Bundred - Publications
1. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncology. 2009 10(2):135-46
2. Bundred NJ. Aromatase inhibitors and bone health. Curr Opin Obstet Gynecol. 2009; 21(1):60-7.
3. Foster FM, Owens TW, Tanianis-Hughes J, Clarke RB, Brennan K, Bundred NJ, Streuli CH. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res. 2009;11(3):R41.
4. Dixon JM, Bundred NJ. Management of Disorders of the Ductal System and Infections. Diseases of the Breast. 4th Edition (2009). Editors Harris J, Lippman ME, Morrow M and Osborne CK. Published by Lippincott Williams & Wilkins. Philadelphia, USA.
5. Barnes NL, Bundred NJ. Treatment of Ductal Carcinoma in Situ. Breast Surgery: A Companion to Specialist Surgical Practice. Fourth Edition. (2009). Editor JM Dixon. Published by Elsevier Saunders. London, UK.
6. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 2008 1;112:1001-10.
7. Bundred NJ. Optimising bone health in survivors of breast cancer. Lancet Oncol. 2007. 8(2):89-91.
8. Bundred NJ. Women’s Health: Breast Pain. Clinical Evidence Handbook. (2007). BMJ Books. Published by Blackwell Publishing.
Lavelle K, Moran A, Howell A, Bundred N, Campbell M, Todd C (2007) Older women with operable breast cancer are less likely to have surgery. Br J Surg (in press).
Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG, Bundred NJ (2007) Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst. 99:616-27.
Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M (2007) Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. Br J Cancer. 96:1197-203
Patiar S, Kirwan CC, McDowell G, Bundred NJ, McCollum CN, Byrne GJ (2007) Prevention of venous thromboembolism in surgical patients with breast cancer. Br J Surg. 94:412-20
Howell A, Clarke RB, Evans G, Bundred N, Cuzick J, Santen R, Allred C (2007) Estrogen deprivation for breast cancer prevention. Recent Results Cancer Res. 174:151-67
Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ (2007) Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer. 96:575-82.
Wilson GR, Cramer A, Welman A, Knox F, Swindell R, Kawakatsu H, Clarke RB, Dive C, Bundred NJ (2006) Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer. 95:1410-4.
Kirwan CC, McCollum CN, Bundred NJ, Byrne GJ (2006) Current UK practice of thromboprophylaxis for breast surgery. Br J Surg. 93:1224-5
Maurice A, Evans DG, Shenton A, Ashcroft L, Baildam A, Barr L, Byrne G, Bundred N, Boggis C, Wilson M, Duffy SW, Howell A (2006) Screening younger women with a family history of breast cancer--does early detection improve outcome? Eur J Cancer. 42:1385-90.
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 98:599-609.
Warnberg F, White D, Anderson E, Knox F, Clarke RB, Morris J, Bundred NJ (2006) Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res. 8:R21
Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ (2006) Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer. 94:253-8.
Dixon JM, Bundred N (2006) Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies. Eur J Surg Oncol. 32:123-5
McDowell G, Temple I, Li C, Kirwan CC, Bundred NJ, McCollum CN, Burton IE, Kumar S, Byrne GJ (2005) Alteration in platelet function in patients with early breast cancer. Anticancer Res. 25:3963-6.
Bundred NJ (2005) The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer. 2005 93:S23-7.
Bundred NJ, Barnes NL (2005) Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer. 93:S10-5
Bundred N (2005) Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. Cancer Invest. 23:173-81.
Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ (2005) Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res. 11:2163-8.
Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ (2005) Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg. 92:429-34.
Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foidart JM, Bundred N, Mol-Arts M, Kubista E (2005) The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG. 112:228-33.
Clarke RB, Bundred NJ (2005) Do early premalignant changes in normal breast epithelial cells predict cancer development? Breast Cancer Res. 7:18-20
Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 90:423-9.
Ahmad T, Farnie G, Bundred NJ, Anderson NG (2004) The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem. 279:1713-9
Down S, Barr L, Baildam AD, Bundred N (2003) Management of accessory breast tissue in the axilla. Br J Surg. 90:1213-4.
Prasad R, Boland GP, Cramer A, Anderson E, Knox WF, Bundred NJ (2003) Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer. 98:2539-46.
Bundred NJ, Morris J (2003) Breast cancer and hormone-replacement therapy: the Million Women Study. Lancet. 36:1329
Boland GP, McKeown A, Chan KC, Prasad R, Knox WF, Bundred NJ (2003) Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast. Br J Cancer. 89:277-83
Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ (2003) Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg. 90:426-32
Freeman SR, Washington SJ, Pritchard T, Barr L, Baildam AD, Bundred NJ (2003) Long term results of a randomised prospective study of preservation of the intercostobrachial nerve. Eur J Surg Oncol. 29:213-5.
Hoey RP, Sanderson C, Iddon J, Brady G, Bundred NJ, Anderson NG (2003) The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer. 88:567-73.
Linforth R, Anderson N, Hoey R, Nolan T, Downey S, Brady G, Ashcroft L, Bundred N (2002) Co-expression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. Clin Cancer Res. 8:3172-7.
Boland GP, Knox WF, Bundred NJ (2002) Molecular markers and therapeutic targets in ductal carcinoma in situ. Microsc Res Tech. 59:3-11
Warnberg F, Bundred N (2002) Will early detection of non-axillary sentinel nodes affect treatment decisions? Br J Cancer. 87:691-3
Bundred NJ, Anderson E, Nicholson RI, Dowsett M, Dixon M, Robertson JF (2002) Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res. 22:2317-9.
Bundred N, Howell A (2002) Fulvestrant (Faslodex): current status in the therapy of breast cancer.
Expert Rev Anticancer Ther. 2:151-60.
Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ, Streuli CH (2002) Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem. 277:27643-50.
Dey P, Bundred N, Gibbs A, Hopwood P, Baildam A, Boggis C, James M, Knox F, Leidecker V, Woodman C (2002) Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trial. BMJ. 324:507.
Chan KC, Knox WF, Gee JM, Morris J, Nicholson RI, Potten CS, Bundred NJ (2002) Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res. 62:122-8.
Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ (2001) ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer. 94:774-82.
Hadjiloucas I, Gilmore AP, Bundred NJ, Streuli CH. Assessment of apoptosis in human breast tissue using an antibody against the active form of caspase 3: relation to tumour histopathological characteristics. Br J Cancer. 2001 85:1522-6.
Bundred NJ, Chan K, Anderson NG (2001) Studies of epidermal growth factor receptor inhibition in breast cancer. Endocr Relat Cancer. 8:183-9.
Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M (2001) Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 61:6739-46.
Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME, Scott T, Muchmore DB (2001) Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev. 10:961-6.
Bundred NJ (2001) Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 27:137-42.
Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS, Bundred NJ (2001) Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg. 88:412-8.
Chan KC, Knox WF, Sinha G, Gandhi A, Barr L, Baildam AD, Bundred NJ (2001) Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer. 91:9-16.
Ghellal A, Li C, Hayes M, Byrne G, Bundred N, Kumar S (2000) Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res. 20:4413-8.
Byrne GJ, Bundred NJ (2000) Surrogate markers of tumoral angiogenesis. Int J Biol Markers. 15:334-9.
Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S (2000) Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 89:122-6.
Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ (2000) Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ. Cancer Res. 60:4284-8.
Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A, Bundred NJ (2000) Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst. 92:1329-36.
Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000 87:214-20.